LNTH - Lantheus expands imaging pipeline into Alzheimer's disease with Cerveau acquisition
- Lantheus Holdings ( NASDAQ: LNTH ) on Monday said it had acquired Cerveau Technologies, a company that uses molecular imaging to help the development of therapies to treat Alzheimer's disease and other cognitive disorders.
- The acquisition gives LNTH access to Cerveau's lead asset MK-6240 - a positron emission tomography imaging agent that targets Tau tangles in Alzheimer's disease.
- As per the deal , LNTH will pay Cerveau an upfront payment and potential additional milestone payments. The figures were not disclosed.
- LNTH will also pay Cerveau double-digit royalty payments for research revenue and commercial sales.
- Lantheus Holdings ( LNTH ) stock earlier closed -1.3% at $60.02.
For further details see:
Lantheus expands imaging pipeline into Alzheimer's disease with Cerveau acquisition